Samsung Bioepis' European Whitepaper Proposes Solutions to Bridge Policy Gaps that Hinder Healthy Market Competition and Timely Access to Biosimilar Medicines

Contributed by: Business Wire

Logo

Tags

Health

Hospitals

Managed Care

General Health

Pharmaceutical

Biotechnology

Biosimilar Medicines

More Like This

Samsung Bioepis to Commercialize BYOOVIZ® (ranibizumab) in Europe from January 2026

Kyung-Ah Kim will serve as the President and Chief Executive Officer (CEO) of Samsung Epis Holdings, in addition to her current role as the President and CEO of Samsung Bioepis.

Newly Established Samsung Epis Holdings to Drive Growth for Samsung Bioepis and a New Subsidiary

Sanofi: Poland's EU Presidency - Paving the Way for a Competitive Pharmaceutical Industry

White Paper: Polish Presidency of the Council of the European Union 2025. Healthcare Policy Recommendations - A Unique Publication from the Institute for Social Policy Development Now Available

Polpharma Group Calls for Urgent Action to Protect early equitable access to medicines for European patients

Samsung Bioepis Reaches Settlement Agreement for PYZCHIVA® (ustekinumab) in Europe

Polpharma Group Supports Urgent EU Action to Safeguard Access to Medicines and Strengthen European Pharmaceutical Sovereignty

PR Newswire associated0

Abbott Broadens Access to Cutting-Edge Biosimilars in Key Emerging Markets